CFAR 1996 Symposium: Frontiers in HIV Therapy

Welcome: Paul A. Volberding, MD and Warner Greene, MD, PhD

Opening Address

  • Haile T. Debas, MD
    Dean, School of Medicine, University of California San Francisco

Morning Session

Moderator: Charles S. Craik, PhD

  • Geographical variation of HIV 1 and HIV 2: indications for vaccine development
    Max Essex, DVM, PhD, Harvard AIDS Institute
  • Development of Novel Anti-HIV Agents; PMPA
    Norbert W. Bischofberger, PhD, Gilead Sciences
  • HIV-1 Protease Inhibitors: What have we learned and what is in the future?
    James Kahn, MD, Associate Professor of Medicine, UCSF; Associate Director, UCSF Center for AIDS Research
  • Mechanisms and Therapeutic Implications of Drug Resistance to HIV-1 Protease Inhibitors
    John Erickson, PhD, Director, Structural Biochemistry Program, NCI-Frederick Cancer Research and Development Center
  • An Overview of Viral Kinetics as it Relates to the Potential for Eradicating HIV
    George M. Shaw, MD, PhD, Professor of Medicine and Microbiology; Deputy Director UAB AIDS Center U of Alabama at Birmingham

Afternoon Session

Moderator: John Greenspan, BDS, PhD

  • New Agents and Targets for HIV-modulation
    H. Clifford Lane, MD, Clinical Director, NIH/NIAID
  • Use of Animal Models to Study Pathogenesis of Primate Lentivirus Infection and Treatment Concepts
    Shiu-Lok Hu, PhD, Executive Director Immunodeficiency/Immunosuppression, Bristol-Myers Squibb Pharmaceutical Research Institute
  • Towards in vivo Gene Therapy for HIV Infection
    Flossie Wong-Staal, PhD, Departments of Medicine and Biology, University of California, San Diego; Director, AIDS Research Institute
  • Gene Therapy Involving Rev Transdominants
    Gary Nabel, MD, PhD, Howard Hughes Medical Institute
  • What is the Future of Gene Therapy to Modulate HIV Disease?
    Lewis T. ("Rusty") Williams, MD, Chiron/UCSF
  • Summary: Warner C. Greene, MD, PhD